Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2020-08-01
2021-11-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Focal Therapy for Localized Prostate Cancer
NCT06270043
Magnetic Resonance Guided Focal Stereotactic Body Radiation Therapy for Localized Prostate Cancer
NCT02163317
Clinical Applications of Integrated PET/MR and PET/CT in the Diagnosis and Treatment of Prostate Cancer.
NCT06355843
Decipher Lethal Prostate Cancer Biology - Urine Metabolomics
NCT03237702
Predictive and Prognostic Markers for Treatment Outcomes in Prostate Cancer Patients
NCT03237026
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Literature showed focal ablation of HIFU or cryotherapy for low and intermediate-risk prostate cancer patients yielded in brilliant outcomes. Biopsy in post-treatment one year showed 87% and 94.6% were negative for clinically significant cancer, respectively. Up to 92% of patients did not need salvage treatment in two years. Ninety-one to one hundred precent of patients had no urinary incontinence, and 74% and 81.5% had no erectile dysfunction, respectively.
This prospective study aims to evaluate the cancer control and quality of life for prostate cancer patients treated with focal therapy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Prostate Health Index
Use Prostate Health Index for the follow-up after focal therapy.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* clinical T2a or less
* Gleason 4+3 or less
* serum PSA less than 20 ng/mL
Exclusion Criteria
* Gleason 4+4 or higher
* serum PSA 20 or higher
* lymph node or distant metastasis
* previous treatment with prostatectomy, radiotherapy, androgen deprivation therapy, HIFU, or cryoablation
40 Years
90 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
China Medical University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Po-Fan Hsieh
Attending Urologist, Department of Urology, China Medical University Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Po-Fan Hsieh
Role: PRINCIPAL_INVESTIGATOR
China Medical University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
China Medical University Hospital
Taichung, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CMUH107-REC3-119
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.